Neuralink, founded by Elon Musk in 2016, develops brain-machine interface (BCI) with a mission to enhance human cognitive capabilities and address neurological conditions. The company aims to bridge the gap between humans and artificial intelligence potentially changing the way humans interact with technology.

Until now, Neuralink had created the N1 implant, capable of reading neural signals and developed a surgical robot designed for insertion of neural threads. After winning the FDA approval to run its clinical trials on humans, they’ve announced their implantation of a device on January 29th.

‍

‍

Neuralink Commences First Trial on Humans

Neuralink CEO, Elon Musk, announced on January 29th that their first implant had been successfully implanted in a human. The implant is a device designed to enable control over computers through thought, aiming to assist individuals with paralysis or neurological conditions.

The scientific community expressed both excitement and caution, raising concerns regarding the device's safety, long-term efficacy, and the trial's transparency.

For more information, you can visit the articles on Nature and Reuters.

‍

Participating in Neuralink's Human Trials: What You Need to Know

In order to join the Prime study you must complete a patient registry form after reviewing the details outlined in the PRIME Study Brochure.

The eligibility criteria for the study is specific, including individuals aged 22 or older with quadriplegia resulting from spinal cord damage or amyotrophic lateral sclerosis (ALS), and with a reliable caregiver. The study is expected to last for six years, with an 18-month primary phase that involves both at-home and clinic visits, followed by a long-term follow-up period of five years. Since this brochure is one of the few official sources of information we have, the lack of public information on Neuralink is a cause for concern.

‍

Neuralink’s Product

IMPLANT

<row>

<col>

The brain-computer interface, designed for full body integration and aesthetic invisibility, enables control of computers or mobile devices from anywhere. The N1 Implant is encapsulated in a biocompatible shell and is able withstand extreme conditions beyond those in the human body. It contains a compact battery that can be wirelessly recharged.

Utilizing advanced, low-energy chips and electronics, it processes and wirelessly transmits neural signals to the Neuralink App, which translates these into actionable commands.

</col>

<col>

‍_{Source: Neuralink}

</col>

</row>

SURGICAL ROBOT

<row>

<col>

The surgical robot is designed to meet the precise insertion requirements of the implant. The robot head contains the optics and sensors from five camera systems, alongside an optical coherence tomography (OCT) system for increased visibility. The needle is finer than a human hair, is designed to grasp, insert, and release the threads with precision.

</col>

<col>

‍_{Source: Neuralink}

</col>

</row>

‍

Neuralink's Financial Data

<row>

<card>

Series D Valuation

<span class="date">2023-08-01</span>
<span class="value">$5B</span>

</card>

<card>

Implied Valuation

<span class="date">2024-01-29</span>
<span class="value">$8.63B</span>

</card>

<card>

Change Since Last Round

<span class="date">2023-08-01 → 2024-01-29</span>

<span class="value green">+72.63%</span>

</card>

</row>

‍

Neuralink vs ApeVue50

‍

ApeVue50 and Neuralink’s 1Y ROI Series

‍

<row>

<col>

ApeVue50 and Neuralink’s ROI:

30D, 60D, 90D, 180D

_{Source: ApeVue}

</col>

<col>

ApeVue50 and Neuralink’s Volatility:

0D, 30D, 60D, 90D, 180D

_{Source: ApeVue}

</col>

</row>

‍

‍